vs
CareCloud, Inc.（CCLD）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
CareCloud, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.8倍（$34.4M vs $19.6M），CareCloud, Inc.同比增速更快（21.9% vs -11.5%），CareCloud, Inc.自由现金流更多（$6.6M vs $-23.1M），过去两年CareCloud, Inc.的营收复合增速更高（15.1% vs -12.2%）
CareCloud, Inc.是一家上市的美国医疗信息技术企业，主要为各类医疗机构、医院提供专业医疗信息化相关服务，公司总部位于新泽西州萨默塞特，目前在全球拥有约四千名员工。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CCLD vs LAB — 直观对比
营收规模更大
CCLD
是对方的1.8倍
$19.6M
营收增速更快
CCLD
高出33.4%
-11.5%
自由现金流更多
CCLD
多$29.6M
$-23.1M
两年增速更快
CCLD
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.4M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 9.1% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | 21.9% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $0.06 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCLDLAB
| Q4 25 | $34.4M | — | ||
| Q3 25 | $31.1M | $19.6M | ||
| Q2 25 | $27.4M | $21.8M | ||
| Q1 25 | $27.6M | $40.8M | ||
| Q4 24 | $28.2M | — | ||
| Q3 24 | $28.5M | $22.1M | ||
| Q2 24 | $28.1M | $22.5M | ||
| Q1 24 | $26.0M | $45.5M |
净利润CCLDLAB
| Q4 25 | — | — | ||
| Q3 25 | $3.1M | $-34.7M | ||
| Q2 25 | $2.9M | $-33.5M | ||
| Q1 25 | $1.9M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.1M | $-26.9M | ||
| Q2 24 | $1.7M | $-45.7M | ||
| Q1 24 | $-241.0K | $-32.2M |
毛利率CCLDLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率CCLDLAB
| Q4 25 | 9.1% | — | ||
| Q3 25 | 10.3% | -168.5% | ||
| Q2 25 | 10.9% | -118.1% | ||
| Q1 25 | 7.3% | -80.8% | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 11.4% | -120.9% | ||
| Q2 24 | 8.1% | -134.5% | ||
| Q1 24 | 0.5% | -132.2% |
净利率CCLDLAB
| Q4 25 | — | — | ||
| Q3 25 | 9.8% | -177.4% | ||
| Q2 25 | 10.6% | -153.7% | ||
| Q1 25 | 7.0% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.9% | -122.0% | ||
| Q2 24 | 6.0% | -203.3% | ||
| Q1 24 | -0.9% | -70.6% |
每股收益（稀释后）CCLDLAB
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.04 | $-0.09 | ||
| Q2 25 | $0.04 | $-0.09 | ||
| Q1 25 | $-0.04 | $-0.07 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.04 | $-0.07 | ||
| Q2 24 | $-0.14 | $-0.12 | ||
| Q1 24 | $-0.10 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $1.2M | — |
| 股东权益账面价值 | $59.5M | $399.7M |
| 总资产 | $87.6M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CCLDLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务CCLDLAB
| Q4 25 | $1.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $336.0K | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CCLDLAB
| Q4 25 | $59.5M | — | ||
| Q3 25 | $57.8M | $399.7M | ||
| Q2 25 | $56.1M | $424.5M | ||
| Q1 25 | $54.2M | $454.6M | ||
| Q4 24 | $49.8M | — | ||
| Q3 24 | $46.5M | $489.3M | ||
| Q2 24 | $43.2M | $510.3M | ||
| Q1 24 | $41.4M | $577.3M |
总资产CCLDLAB
| Q4 25 | $87.6M | — | ||
| Q3 25 | $90.6M | $539.6M | ||
| Q2 25 | $75.2M | $557.0M | ||
| Q1 25 | $73.6M | $579.6M | ||
| Q4 24 | $71.6M | — | ||
| Q3 24 | $70.7M | $681.5M | ||
| Q2 24 | $74.0M | $708.7M | ||
| Q1 24 | $76.9M | $777.7M |
负债/权益比CCLDLAB
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $-23.1M |
| 自由现金流率自由现金流/营收 | 19.0% | -118.1% |
| 资本支出强度资本支出/营收 | 6.2% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $23.8M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CCLDLAB
| Q4 25 | $8.7M | — | ||
| Q3 25 | $7.4M | $-22.2M | ||
| Q2 25 | $7.4M | $-20.7M | ||
| Q1 25 | $5.1M | $-30.3M | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $7.1M | $-27.9M | ||
| Q2 24 | $4.3M | $-39.0M | ||
| Q1 24 | $4.1M | $-62.5M |
自由现金流CCLDLAB
| Q4 25 | $6.6M | — | ||
| Q3 25 | $6.5M | $-23.1M | ||
| Q2 25 | $6.2M | $-22.6M | ||
| Q1 25 | $4.5M | $-35.3M | ||
| Q4 24 | $4.3M | — | ||
| Q3 24 | $6.7M | $-30.1M | ||
| Q2 24 | $4.2M | $-41.0M | ||
| Q1 24 | $3.8M | $-63.3M |
自由现金流率CCLDLAB
| Q4 25 | 19.0% | — | ||
| Q3 25 | 20.9% | -118.1% | ||
| Q2 25 | 22.8% | -103.6% | ||
| Q1 25 | 16.2% | -86.6% | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 23.6% | -136.4% | ||
| Q2 24 | 14.8% | -182.2% | ||
| Q1 24 | 14.5% | -138.9% |
资本支出强度CCLDLAB
| Q4 25 | 6.2% | — | ||
| Q3 25 | 2.8% | 4.5% | ||
| Q2 25 | 4.2% | 8.7% | ||
| Q1 25 | 2.3% | 12.4% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 1.2% | 10.2% | ||
| Q2 24 | 0.5% | 8.6% | ||
| Q1 24 | 1.1% | 1.7% |
现金转化率CCLDLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.62× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCLD
| Healthcare IT | $31.0M | 90% |
| Medical Practice Management | $3.4M | 10% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
